Business
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
CHICAGO, June 05, 2025--MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/4a367b71d827bc712a468dde74eb7843"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GY3H7diVIDVIrMNfQp4BWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4a367b71d827bc712a468dde74eb7843","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hPuWxgCNYyxVK2i2jxqlnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4a367b71d827bc712a468dde74eb7843","width":1000,"height":380}},"lazy":false},{"type":"text","content":"Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data","length":100,"tagName":"p"},{"type":"text","content":"CHICAGO, June 05, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy.","length":570,"tagName":"p"},{"type":"text","content":"As of May 15, 2025, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis continues to demonstrate a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. The treatment has been generally well-tolerated to date in this heavily pre-treated population.1 Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.2-3","length":593,"tagName":"p"},{"type":"text","content":""It is gratifying to see that our treatment further extends lives for these hard-to-treat patient populations, especially in third-line NSCLC treatment where patients are most resistant to t...